These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 469146

  • 1. Fluphenazine enanthate in the outpatient treatment of late paraphrenia.
    Raskind M, Alvarez C, Herlin S.
    J Am Geriatr Soc; 1979 Oct; 27(10):459-63. PubMed ID: 469146
    [Abstract] [Full Text] [Related]

  • 2. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
    Citrome L, Jaffe A, Levine J.
    Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
    Chouinard G, Annable L, Ross-Chouinard A.
    Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Fluphenazine decanoate and fluphenazine enanthate in the out-patient management of chronic schizophrenia.
    MacCrimmon DJ, Saxena B, Foley P, Grof P.
    Neuropsychobiology; 1978 Mar; 4(6):360-5. PubMed ID: 692838
    [Abstract] [Full Text] [Related]

  • 7. Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
    Uchida T, Suzuki T, Sakurai H, Tsutsumi C, Den R, Mimura M, Uchida H.
    Int Clin Psychopharmacol; 2013 Sep; 28(5):261-6. PubMed ID: 23820334
    [Abstract] [Full Text] [Related]

  • 8. Cocaine use by schizophrenic outpatients who receive depot neuroleptic medication.
    Stone AM, Greenstein RA, Gamble G, McLellan AT.
    Hosp Community Psychiatry; 1993 Feb; 44(2):176-7. PubMed ID: 8432504
    [No Abstract] [Full Text] [Related]

  • 9. Depot fluphenazine decanoate and enanthate for schizophrenia.
    David A, Adams CE, Eisenbruch M, Quraishi S, Rathbone J.
    Cochrane Database Syst Rev; 2005 Jan 25; (1):CD000307. PubMed ID: 15674872
    [Abstract] [Full Text] [Related]

  • 10. A double-blind comparison of fluphenazine and haloperidol in outpatient schizophrenic children.
    Engelhardt DM, Polizos P, Waizer J, Hoffman SP.
    J Autism Child Schizophr; 1973 Jan 25; 3(2):128-37. PubMed ID: 4583792
    [No Abstract] [Full Text] [Related]

  • 11. Depot fluphenazine: risk/benefit ratio.
    Glazer WM.
    J Clin Psychiatry; 1984 May 25; 45(5 Pt 2):28-35. PubMed ID: 6370986
    [Abstract] [Full Text] [Related]

  • 12. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.
    Levine J, Schooler NR, Severe J, Escobar J, Gelenberg A, Mandel M, Sovner R, Steinbook R.
    Adv Biochem Psychopharmacol; 1980 May 25; 24():483-93. PubMed ID: 6996445
    [No Abstract] [Full Text] [Related]

  • 13. Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation.
    Soni SD, Sampath G, Shah A, Krska J.
    Acta Psychiatr Scand; 1992 May 25; 85(5):354-9. PubMed ID: 1351333
    [Abstract] [Full Text] [Related]

  • 14. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
    Cohen BM, Waternaux C, Chouinard G, Sommer BR, Jones B.
    J Clin Psychopharmacol; 1985 Dec 25; 5(6):328-32. PubMed ID: 4066997
    [Abstract] [Full Text] [Related]

  • 15. Controlled trial of depot fluphenazine in out-patient schizophrenics.
    Crawford R, Forrest A.
    Br J Psychiatry; 1974 Apr 25; 124(0):385-91. PubMed ID: 4599422
    [No Abstract] [Full Text] [Related]

  • 16. Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression.
    Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC.
    Br J Psychiatry; 1985 May 25; 146():469-74. PubMed ID: 3893599
    [Abstract] [Full Text] [Related]

  • 17. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T.
    J Psychiatry Neurosci; 1994 Jul 25; 19(4):254-64. PubMed ID: 7918346
    [Abstract] [Full Text] [Related]

  • 18. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
    Inderbitzin LB, Lewine RR, Scheller-Gilkey G, Swofford CD, Egan GJ, Gloersen BA, Vidanagama BP, Waternaux C.
    Am J Psychiatry; 1994 Dec 25; 151(12):1753-9. PubMed ID: 7977881
    [Abstract] [Full Text] [Related]

  • 19. High dosage treatment with fluphenazine intravenously followed by depot injections in acute schizophrenia.
    Fleischhauer J.
    Int Pharmacopsychiatry; 1980 Dec 25; 15(1):6-13. PubMed ID: 7390720
    [Abstract] [Full Text] [Related]

  • 20. Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
    Stanković Z, Britvić D, Vuković O, Ille T.
    Psychiatr Danub; 2008 Mar 25; 20(1):42-52. PubMed ID: 18376330
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.